Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Cannon, C. P., Husted, S., Harrington, R. A., Scirica, B. M., Emanuelsson, H., Storey, R. F. 2007; 50 (19): 1844-1851
View details for DOI 10.1016/j.jacc.2007.07.053
View details for Web of Science ID 000250788300005